A Phase II, randomized, double-blind, placebo-controlled, 2-part study to evaluate the safety, tolerability, pharmacokinetics, clinical response, and antiviral activity of orally administered study drug regimens in hospitalized or non-hospitalized infants and children aged 28 days to 24 months infected with RSV (respiratory syncytial virus).
Explore related content and topics
Blog
The RACE for Children Act
In the US, legislation such as the Better Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) have helped to…
White Paper
The Impact Of Contraceptive Requirements On Pediatric Clinical Trials
Contraceptive requirements applied to women of child-bearing potential participating in clinical trials also apply to children participating in…
Blog
Decentralized Clinical Trials: Speaking the Same Language
The pandemic has accelerated adoption of clinical trial models that lessen the burden of participation on the patient and family care circle.…